双金连合剂治疗风热型感冒患者的成本-效果分析  

The Cost-effectiveness Analysis of Shuangjinlian Mixture for the Treatment of Patients of Hot-wind Cold Type

作　　者：程莉丽 苏风山 CHENG Li-Li;SU Feng-Shan(Jiangsu Medical Insurance Research Institute,Medical Insurance Medical Device Professional Committee,Nanjing 210015,China;Henan Taloph Pharmaceutical Limited by Share Ltd,Zhengzhou 450007,China)

机构地区：[1]江苏省医疗保险研究会医保医药医疗器械专业委员会,南京210015 [2]河南太龙药业股份有限公司,郑州450007

出　　处：《中国药物经济学》2021年第2期14-21,27,共9页China Journal of Pharmaceutical Economics

摘　　要：目的比较双金连合剂与双黄连口服液治疗风热型感冒患者的成本-效果,为相关部门提供决策依据。方法根据两个不同临床终点(退热、所有症状消退),建立两个决策树模型(M1和M2),用成本-效果比值(ICER)比较两方案的经济学,并进行敏感性分析来验证结果稳定性。结果在以退热为终点的主要情境下,以24 h退热有效率为效果指标(M1)时的ICER为0.31元,以质量调整生命年(QALY)为效果指标(M2)时,ICER为12015.02元;在以所有症状消退为终点的主要情境下,以3 d所有症状消退率为效果指标(M1)时的ICER为2.17元,以QALY为效果指标(M2)时,ICER为21245.01元。敏感性分析中各因素对研究结论无明显影响。结论双金连合剂对比双黄连口服液治疗风热型感冒在以退热有效率和所有症状消退为主要终点情境下,ICER值低于各自的阈值,结果具有成本-效果。Objective To compare the cost-effectiveness of Shuangjinlian mixture and Shuanghuanglian Oral Liquid for the treatment of patients with hot-wind cold and provide decision-making for some departments.Methods A total of 2 decision tree models(M1 and M2)were established according to 2 different clinical endpoints(antipyretic,regression of all symptoms).Cost-effectiveness ratio(ICER)was obtained to compare the cost-effectiveness of the two regimen.Sensitivity analysis was performed to verify the stability of the results.Results In the main scenario with the end point of antipyretic fever(scenario 1),the ICER value with the 24-hour effective rate in M1 was ￥0.31/1%,and the ICER value in M2 was ￥12015.02/QALY.In the main scenario with all symptom regression as the end point,the ICER was 2.17 yuan when all symptoms subsided on the 3 rd day as the effect index(M1),and the ICER was 21245.01 yuan when QALY was the effect index(M2).The various factors in the sensitivity analysis had no obvious influence on the research conclusion.Conclusion When Shuangjinlian Mixture was compared with Shuanghuanglian Oral Liquid in the treatment of wind-heat cold.In the context of the effective rate of antipyretic and the resolution of all symptoms as the primary endpoint,the ICER value is lower than the respective threshold,and the result is cost-effective.

关 键 词：双金连合剂 双黄连口服液 风热型感冒 成本-效果 

分 类 号：R254.1[医药卫生—中医内科学] R956[医药卫生—中医学]